Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Wild-type (senile) ATTR amyloidosis is similar to familial ATTR amyloidosis, except the protein that is deposited is the normal, non-mutated transthyretin protein. The normal transthyretin protein is less prone to forming amyloid deposits than the mutated form.
As a result, patients only develop the disease in older age, usually at 65 years of age or older. Because amyloid deposits accumulate slowly in this form of the disease, the prognosis is generally better than AL (primary) amyloidosis and familial ATTR amyloidosis.
Treatment is generally aimed at the symptoms of wild-type (senile) ATTR amyloidosis, such as treating amyloid deposits in the heart. Because the heart is the most commonly affected organ, your disease will be monitored and treated by a cardiologist.
For some patients with severe wild-type (senile) ATTR amyloidosis, a heart transplant may be the best option. Stanford is one of the world's leading centers for heart transplantation for amyloidosis.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.